Put Options

16 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$64.0 - $116.06 $8.96 Million - $16.2 Million
140,000 Added 150.7%
232,900 $15.6 Million
Q2 2024

Aug 13, 2024

SELL
$110.31 - $140.45 $8.2 Million - $10.4 Million
-74,300 Reduced 44.44%
92,900 $10.5 Million
Q1 2024

May 15, 2024

SELL
$114.22 - $140.1 $31.3 Million - $38.4 Million
-273,900 Reduced 62.09%
167,200 $23.2 Million
Q4 2023

Feb 14, 2024

BUY
$75.49 - $124.16 $19.9 Million - $32.8 Million
264,000 Added 149.07%
441,100 $54.7 Million
Q3 2023

Nov 14, 2023

BUY
$86.06 - $137.93 $4.77 Million - $7.64 Million
55,400 Added 45.52%
177,100 $16.5 Million
Q2 2023

Aug 14, 2023

BUY
$112.47 - $130.98 $13.7 Million - $15.9 Million
121,700 New
121,700 $15.6 Million
Q4 2022

Feb 13, 2023

SELL
$84.98 - $122.67 $4.55 Million - $6.58 Million
-53,600 Reduced 76.24%
16,700 $1.89 Million
Q3 2022

Nov 14, 2022

SELL
$76.35 - $94.18 $274,860 - $339,048
-3,600 Reduced 4.87%
70,300 $5.66 Billion
Q2 2022

Aug 12, 2022

BUY
$67.99 - $132.89 $5.02 Million - $9.82 Million
73,900 New
73,900 $5.51 Million
Q4 2020

Feb 12, 2021

SELL
$78.0 - $104.5 $826,800 - $1.11 Million
-10,600 Closed
0 $0
Q3 2020

Nov 13, 2020

BUY
$95.51 - $112.95 $1.01 Million - $1.2 Million
10,600 New
10,600 $1.09 Million
Q3 2019

Nov 13, 2019

SELL
$35.53 - $43.8 $195,415 - $240,899
-5,500 Closed
0 $0
Q2 2019

Aug 12, 2019

BUY
$27.84 - $38.92 $83,520 - $116,760
3,000 Added 120.0%
5,500 $824,000
Q4 2018

Feb 13, 2019

SELL
$26.99 - $37.37 $529,004 - $732,452
-19,600 Reduced 88.69%
2,500 $300,000
Q3 2018

Nov 14, 2018

BUY
$23.35 - $36.72 $403,955 - $635,256
17,300 Added 360.42%
22,100 $3.16 Million
Q2 2018

Aug 14, 2018

BUY
$17.54 - $25.22 $84,192 - $121,056
4,800 New
4,800 $456,000

Others Institutions Holding DXCM

About DEXCOM INC


  • Ticker DXCM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 386,257,984
  • Market Cap $29.5B
  • Description
  • DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM ...
More about DXCM
Track This Portfolio

Track Capital Fund Management S.A. Portfolio

Follow Capital Fund Management S.A. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital Fund Management S.A., based on Form 13F filings with the SEC.

News

Stay updated on Capital Fund Management S.A. with notifications on news.